Company profile for Annovis Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Our drug attacks neurodegeneration by improving axonal transport, the information highway of the nerve cell, which has been shown to be the cause of nerve cell degeneration and ultimately death. With an aging population, neurodegenerative diseases have become one of the world’s largest unmet medical needs. Annovis understands how the brain works and how brain cells die. Nerve cell death is the underlying cause of all neur...
Our drug attacks neurodegeneration by improving axonal transport, the information highway of the nerve cell, which has been shown to be the cause of nerve cell degeneration and ultimately death. With an aging population, neurodegenerative diseases have become one of the world’s largest unmet medical needs. Annovis understands how the brain works and how brain cells die. Nerve cell death is the underlying cause of all neurodegenerative disease in both slow chronic and fast acute injuries to the brain

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1055 Westlakes Drive Suite 300 Berwyn, PA 19312
Telephone
Telephone
+1 (610) 727-3913
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/03/3198821/0/en/Annovis-To-Present-at-the-2025-Annual-Meeting-of-the-Parkinson-Study-Group.html

GLOBENEWSWIRE
03 Dec 2025

https://www.globenewswire.com/news-release/2025/11/24/3193415/0/en/Annovis-Announces-Two-Presentations-at-the-CTAD-2025-Conference.html

GLOBENEWSWIRE
24 Nov 2025

https://www.globenewswire.com/news-release/2025/11/18/3189956/0/en/Annovis-Announces-FDA-Meeting-to-Discuss-Parkinson-s-Disease-Dementia-Program-Reaffirms-FDA-Alignment-on-Pivotal-Phase-3-Alzheimer-s-Disease-Study.html

GLOBENEWSWIRE
18 Nov 2025

https://www.globenewswire.com/news-release/2025/11/17/3189111/0/en/Annovis-Reports-New-Biomarker-Data-Linking-Amyloid-Co-Pathology-to-Accelerated-Cognitive-Decline-in-Parkinson-s-Patients.html

GLOBENEWSWIRE
17 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186220/0/en/Annovis-Provides-Corporate-Updates-and-Reports-Third-Quarter-2025-Financial-Results.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/06/3182499/0/en/Annovis-Achieves-Significant-Milestones-and-Sustains-Strong-Progress-in-Phase-3-Alzheimer-s-Program.html

GLOBENEWSWIRE
06 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty